| Document |
Document Title |
|
WO/2002/059104A1 |
The invention relates to rustmicin derivatives of formula (I) wherein the radicals have the following designations: R?1¿ represents hydrogen or -C(=O)R?5¿; R?2¿ represents -CH¿2?-OR?6¿, -CH¿2?-SR?6¿ or =CH¿2?; R?3¿ represents OC...
|
|
WO/2002/048135A1 |
TAK1 inhibitors or TAK1 activation inhibitors containing as the active ingredient zearalenones having hydroxyl groups at both of the 8- and 9-positions; a method of inhibiting TAK1 or a method of inhibiting the activation of TAK1 by usin...
|
|
WO/2002/048136A1 |
Keratinocyte proliferation inhibitors containing one or more zearalenones as the active ingredient; remedies or preventives for skin diseases in association with the abnormal proliferation of keratinocytes; a method of inhibiting the pro...
|
|
WO/2002/040463A1 |
A macrocyclic compound represented by the following formula (1), its salt or its ester. This compound, which can be obtained by fractionating components extracted from a marine algae (for example, $i(Sargassum micracanthum Endlicher) bel...
|
|
WO/2002/036538A1 |
A process for producing an esterificated condensate, wherein a monomeric ester or thioester, or a polyester or polythioester is produced by carrying out a direct condensation reaction from a carboxylic acid and an equimolar amount of an ...
|
|
WO/2002/036533A1 |
Monomers having electron-withdrawing groups, as represented by the general formula (a), (b) or (c), wherein A?1¿, A?2¿, and A?3¿ are each a ring; R?a¿, R?b¿, R?c¿, and R?u¿ are each independently hydrogen or an organic group; at l...
|
|
WO/2002/032916A2 |
The present invention provides novel sixteen-membered macrolide compounds that are useful as anti-infective agents or as intermediates thereto. The present invention also provides methods for the preparation of these compounds, and metho...
|
|
WO/2002/030356A2 |
The present invention relates to methods for use in producing epothilones and analogs and derivatives thereof. A general method according to the present invention broadly comprises performing an aldol condensation of a first compound wit...
|
|
WO/2002/028820A1 |
The present invention relates to a compound of formula (I) in which X, A, T, Y, G and R are as defined in Claim (1).
|
|
WO/2002/026856A1 |
An optical device comprises a substrate and at least one semiconductive polymer supported by said substrate, wherein said semiconductive polymer is a copolymer in which one of the repeat units is a group of formula (I) below or a homopol...
|
|
WO/2002/016369A2 |
The present invention relates to compounds having the structure (1) (and pharmaceutically acceptable derivatives thereof), wherein R¿1?-R¿4?, Z, X, A-B, D-E, G-J, and K-L are as defined herein, the synthesis thereof and the use of thes...
|
|
WO/2002/016345A2 |
Macrocyclic ester compounds may be produced from oligoesters by thermal cleavage in the presence of a thermostable benzene derivative.
|
|
WO/2002/012223A2 |
The present invention provides compounds having improved stability over that of natural benzolactones, and a process for synthesizing these compounds. These compounds exhibit anti-cancer activity and inhibit V-ATPase activity.
|
|
WO/2002/012534A2 |
The present invention relates to compounds made by a subset of modules from one or more polyketide synthase ('PKS') genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring p...
|
|
WO/2002/007761A1 |
The present invention features methods for inhibiting HCV replication and processing by targeting heat shock protein 90 (HSP90). HSP90 is a cellular chaperone protein that was found to be an essential factor in NS2/3 self-cleavage. HSP90...
|
|
WO/2002/008218A1 |
The invention relates to cyclic substituted aminomethyl compounds of general formula IA and IB, methods for production thereof, intermediates in said production methods, a medicament containing at least one of said cyclic substituted ami...
|
|
WO/2001/081291A2 |
Applicants have developed a process for the oxidation of ketones to esters. The process involves contacting a ketone with hydrogen peroxide and a catalyst at oxidation conditions. The catalyst is a molecule sieve represented by the empir...
|
|
WO/2001/068636A1 |
The invention relates to a method for carrying out a Baeyer-Villiger oxidation of organic carbonyl compounds.
|
|
WO/2001/066501A1 |
A process for the preparation of compounds of the general formula (3) or (8) which comprises reacting a compound (1) having an electron-withdrawing group with a compound (2) or (7) in the presence of both a catalyst comprising a compound...
|
|
WO/2001/060768A1 |
A process suitable for safely mass-producing, through a short step, cyclic compounds useful in medicines, agricultural chemicals, foods, cosmetics, and chemical products or as intermediates therefor. The process, which is for producing a...
|
|
WO/2001/055129A1 |
A method for the production of a macrocyclic monomer ( for example, ethylene brassylate) comprises the following steps: treatment of a polymer (for example, polyethylene brassylate) with a supercritical fluid, under conditions which brin...
|
|
WO/2001/054687A1 |
Topically administrable anti-allergy compositions comprising olopatadine and a polymeric quaternary ammonium preservative are suitable for use by patients wearing contact lenses.
|
|
WO/2001/047889A1 |
Novel tricyclic compounds of general formula (I) or pharmacologically acceptable salts thereof, exhibiting leukotriene antagonism, wherein R?1¿ is halogeno or the like; R?2¿ is nitro or the like; A is a group derived from a five- or si...
|
|
WO/2001/032644A2 |
Compounds for formula (I) in which: Y represents O, NR?a¿, S, SO or SO¿2?; X?1¿ represents (CR?1¿R?2¿)m; X?2¿ represents (CR?3¿R?4¿)n; one of m and n is 1 and the other is 0 or 1; and R?1¿, R?2¿, R?3¿ and R?4¿ are each as def...
|
|
WO/2001/014360A2 |
This invention relates to new RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; t...
|
|
WO/2001/009113A2 |
The invention relates to compounds of general formula (I) wherein R stands for a group of general formula -COOR?1¿, -CONR?2¿R?3¿, -CONR?4¿CONR?4¿R?5¿ or -CH¿2?OR?6¿, wherein R?1¿ stands for a C¿2-6? alkyl group; a C¿1-6? alkyl...
|
|
WO/2001/009094A2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by s...
|
|
WO/2001/009138A2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by (...
|
|
WO/2001/002413A1 |
The invention provides compounds of formula (II), wherein R is -H or -CO-CH=CH-COOH, and pharmaceutically acceptable salts and esters thereof. Processes for the preparation of the compounds, pharmaceutical compositions containing them, a...
|
|
WO/2000/075127A1 |
Compounds represented by general formula (1) or pharmaceutically acceptable salts thereof. In said formula, X is CH, CH¿2?, CHR (wherein R is lower alkyl or substituted lower alkyl), or CRR' (wherein R and R' are each as defined above a...
|
|
WO/2000/075126A1 |
The present invention provides, inter alia, polyketide macrolides including a polyketide macrolide of structure (2) wherein R?1¿-R?5¿ are the same or different and each is independently selected from the group consisting of hydrogen, R...
|
|
WO/2000/073289A1 |
The invention relates to novel aryl-substituted S(O)¿m? cycles of formula (I), in which F?1¿, F?2¿, G, V, W, X, Y, Z and m have the meanings defined in the description. The invention further relates to methods for producing said cycle...
|
|
WO/2000/068203A1 |
Compounds of general formula (1) or salts thereof, exhibiting preventive and therapeutic effects against HIV infections wherein R?1¿ is an optionally substituted five- or six-membered ring group; X?1¿ is a free valency or the like; W i...
|
|
WO/2000/064445A1 |
Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure (I) wherein n is 0 to 4; X is a bond, O, S, SO, SO¿2?, CO, (a), or NR?7¿; Y is a bond, O, S, SO, SO¿2?, CO, (b) or NR?7'¿ wherein...
|
|
WO/2000/058338A1 |
Disclosed are compositions and methods for promoting plant growth. The compounds are cyclopropyl-, cyclobutyl- and cyclopentyl-substituted brassinosteroids having high growth promoting ability. They may be used alone or in combination wi...
|
|
WO/2000/058322A1 |
The invention discloses ruthenium alkylidene of the type (PCy¿3?)(L)C1¿2?Ru(CHPh), where L is a triazolylidene ligand of the general formula (I). These catalysts have been found to be considerably more active for olefin metathesis at e...
|
|
WO/2000/053593A1 |
A process for the preparation of esters or lactones, which comprises reacting a ketone represented by general formula (1) (wherein R?a¿ and R?b¿ are each independently an organic group having a carbon atom at the position where the car...
|
|
WO/2000/049011A1 |
The present invention provides 7-14 membered ring ether protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compound...
|
|
WO/2000/038674A1 |
Compounds which induce degradation of mRNA which contains one or more mRNA instability sequences are provided for use as pharmaceuticals, e.g. for use in the prophylaxis or treatment of diseases and medical conditions in general having a...
|
|
WO/2000/039314A1 |
A method is provided for the identification of a compound which affects mRNA stability, in particular induces mRNA degradation, in which a DNA expression system which in the absence of test compound is capable of expressing a protein hav...
|
|
WO/2000/039113A1 |
The present invention relates to benzopyrans and benzoxepines of formula (I), wherein X, A, R¿1?, R¿2? and (R)¿p? have the meanings as given in claim 1, which can be used in the treatment of dislipidaemias, atherosclerosis and diabete...
|
|
WO/2000/031247A2 |
Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) of sorangium cellulosum are used to express recombinant PKS genes in host cells for the production of epithilones, epothilone derivatives,...
|
|
WO/2000/027802A1 |
This invention concerns compounds for inhibiting intracellular signal transduction, especially intracellular signal transduction mediated by one or more molecular interactions involving a phosphotyrosine-containing protein. This inventio...
|
|
WO/2000/027627A1 |
In its first aspect, the invention is directed to a solid support mediated method for the synthesis of diverse polycyclic heterocycles according to general formula (V). A second aspect of the invention is directed to a solid support boun...
|
|
WO/2000/023417A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
|
WO/2000/023416A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
|
WO/2000/023415A1 |
The present invention relates to compounds of general formula (I). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PP...
|
|
WO/2000/014033A1 |
Nucleophilic oxygen species, such as primary alcohols, carboxylates, and water, are added to vinyl epoxides in a highly regioselective and enantioselective manner, providing a convenient route to enantiomerically enriched 2,2-diols and o...
|
|
WO/2000/010965A2 |
This invention is to provide a compound for antagonizing CCR5, said compound being represented by formula (I), wherein R?1¿ is an optionally substituted phenyl or an optionally substituted thienyl; Y is -CH¿2?-, -S- or -O-; and R?2¿, ...
|
|
WO/2000/004892A2 |
This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development ...
|
